Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck’s problems in China seem to be getting worse, raising questions about the company’s growth. Trouble with sales of Merck ...

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV ...

US stocks open little moved by China's retaliatory tariffs. Mexico and Canada's tariff pauses suggests tariffs are ...

Merck shares fell in pre-market US trade after the drugmaker posted lower sales of its HPV vaccine Gardasil – with shipments to China paused - and signalled a weaker 2025 outlook.

HPV vaccines aim to prevent the development of HPV-related cancers by stopping the viral infection from taking hold in the ...

Cervical cancer is one of the most preventable cancers, yet it remains a significant health threat. Here’s why prevention is ...